A Vaccine Approach for the Prevention of Infections by Multidrug-resistant Enterococcus faecium |
| |
Authors: | Srinivas Kodali Evgeny Vinogradov Fiona Lin Nancy Khoury Li Hao Vilo Pavliak C Hal Jones Diana Laverde Johannes Huebner Kathrin U Jansen Annaliesa S Anderson Robert G K Donald |
| |
Institution: | From ‡Pfizer Vaccine Research and Early Development, Pearl River, New York 10654.;the §National Research Council, Ottawa, Ontario K1A 0R6, Canada.;the ¶Division of Infectious Diseases, Department of Medicine, University Hospital, Hugstetter Strasse 55, 79106 Freiburg, Germany, and ;the ‖Department of Pediatrics, Dr. von Hauner Children''s Hospital, Ludwig-Maximilians-University, Lindwurmstrasse 4, 80338 Munich, Germany |
| |
Abstract: | The incidence of multidrug-resistant Enterococcus faecium hospital infections has been steadily increasing. With the goal of discovering new vaccine antigens, we systematically fractionated and purified four distinct surface carbohydrates from E. faecium endocarditis isolate Tx16, shown previously to be resistant to phagocytosis in the presence of human serum. The two most abundant polysaccharides consist of novel branched heteroglycan repeating units that include signature sugars altruronic acid and legionaminic acid, respectively. A minor high molecular weight polysaccharide component was recognized as the fructose homopolymer levan, and a glucosylated lipoteichoic acid (LTA) was identified in a micellar fraction. The polysaccharides were conjugated to the CRM197 carrier protein, and the resulting glycoconjugates were used to immunize rabbits. Rabbit immune sera were evaluated for their ability to kill Tx16 in opsonophagocytic assays and in a mouse passive protection infection model. Although antibodies raised against levan failed to mediate opsonophagocytic killing, the other glycoconjugates induced effective opsonic antibodies, with the altruronic acid-containing polysaccharide antisera showing the greatest opsonophagocytic assay activity. Antibodies directed against either novel heteroglycan or the LTA reduced bacterial load in mouse liver or kidney tissue. To assess antigen prevalence, we screened a diverse collection of blood isolates (n = 101) with antibodies to the polysaccharides. LTA was detected on the surface of 80% of the strains, and antigens recognized by antibodies to the two major heteroglycans were co-expressed on 63% of these clinical isolates. Collectively, these results represent the first steps toward identifying components of a glycoconjugate vaccine to prevent E. faecium infection. |
| |
Keywords: | antigen carbohydrate structure Enterococcus teichoic acid vaccine |
|
|